NOVEL PRE-STROKE ANTI-BODY SYSTEMS AND THEIR USES
Patent Information
- Application Number
- ARP20250100480
- Authority / Receiving Office
- AR · AR
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-02-20
- Filing Date
- 2025-02-20
- Publication Date
- 2026-08-19
Claims
The present invention relates to novel antibodies that bind to antigens on target cells, such as tumor cells, and that direct radionuclides to such cells, to uses of such antibodies, and to methods for preparing them.
1. An antibody assembly comprising: i) a first antibody that binds to an antigen expressed on the surface of a target cell, and further comprising a VH domain of an antigen-binding site for a radiolabeled compound, but not comprising a VL domain of an antigen-binding site for the radiolabeled compound, or comprising a VL domain that is not effective in forming, together with the VH domain, an antigen-binding site for said radiolabeled compound;and ii) a second antibody that binds to said antigen expressed on the surface of the target cell, and further comprising a VL domain of an antigen-binding site for the radiolabeled compound, but not comprising a VH domain of an antigen-binding site for the radiolabeled compound, or comprising a VH domain that is not effective in forming, together with the VL domain, an antigen-binding site for said radiolabeled compound, wherein said VH domain of the first antibody and said VL domain of the second antibody are together capable of forming a functional antigen-binding site for the radiolabeled compound, and wherein each of the VH or VL domains is linked through its N-terminus region to the C-terminus of one of the two heavy chains of the first or second antibody by means of a peptide ligand selected from GGGSGGGGGSGGGGGSGGGGSGG (SEQ ID No. 35) or GGGGGSGGGSGGGGSGGSGG (SEQ ID No. 36).
39. A pharmaceutical composition comprising the set of antibodies according to any of claims 1-38 together with pharmaceutically acceptable excipients.
40. A pharmaceutical composition comprising a first or second antibody according to any of claims 1-38 together with pharmaceutically acceptable excipients.
43. A set of nucleic acids expressing the set of antibodies according to any of claims 1-38.
44. An expression vector or set of expression vectors comprising the set of nucleic acids according to claim 43.
45. A host cell or set of host cells comprising the expression vector or set of expression vectors according to claim 44.